Volume 8, Issue 1, March 2020, Page: 8-12
A Survey of the Cardiology Care Delivered to Cancer Patients in Nigeria
Alikor Chizindu Akubudike, Department of Medicine, Faculty of Clinical Sciences, College of Health Sciences, University of Port Harcourt, Port Harcourt, Nigeria
Weje Chituru Chioma, Department of Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
Received: Nov. 21, 2019;       Accepted: Dec. 9, 2019;       Published: Jan. 17, 2020
DOI: 10.11648/j.crj.20200801.12      View  570      Downloads  154
Abstract
BACKGROUND: The incidence of cardiovascular disease is on the rise and this is no less so amongst the population of individuals who are affected by cancer as improvement over the years in cancer treatment options have brought about improved outcomes in terms of overall patient survival and outcomes but has additionally also illuminated the side effects of these cancer treatment as patients live longer to manifest them thereby increasing morbidity and mortality. In Nigeria, there is paucity of data on cardio-oncology and this study will be the first documented study assessing the level of knowledge and the activity of cardiology care provided to oncology patients who develop cardiovascular disease in Nigeria and will therefore serve as a template towards the development of cardio-oncology services in Nigeria. METHODS: The survey was questionnaire-based involving cardiologist in Nigeria. They first part assessed the demographic characteristics of participants. The second part of the questionnaire assessed participants’ self-admitted expertise in the management of cardiovascular conditions complicating cancer treatment. RESULTS: There were more male (57.14%) than female (42.86%) respondents. More than two-thirds of respondents (71.4%, n=55) were aged 30-44 year. Cumulatively, the South-south and South-western regions accounted for over two-thirds of responses (72.43%, n=55). Over three-thirds of respondents (83.12%, n=) worked at teaching hospitals. Majority (89.5%, n=68) of ambulatory cancer patients in need of cardiology care received this service in a general cardiology clinic with only 10.5% (n=8) receiving care at a cardio-oncology centre. Majority of respondents (67.1%, n=51) dId not receive referrals from general practitioners or other specialists to evaluate cardiac problems in patients who had received cancer treatment. 80.5% of participants (n=62) said that they either did not know about the ESC position paper or knew about it but did not apply its suggestions to their practice. CONCLUSION: Most cancer patients requiring cardiovascular care are seen in the general cardiology clinic of Government owned hospitals in Nigeria. Although the knowledge of cardiologists in the management of cardiovascular complications of cancer patients is adequate, referral from General Practitioners is low. The ESC position paper on cardio-oncology is poorly known and utilized by cardiologist in the care of cancer patients with cardiovascular complications with the field of cardio-oncology generally regarded as a new topic in cardiology requiring more information on its dissemination and acceptance. This survey therefore makes obvious the dearth of knowledge regarding cardio-oncology that is prevalent in Nigeria. It is hoped that this will ignite a change in this aspect. There is therefore an urgent need to for all stakeholders to join force together towards the development of cardio-oncology skills and services in Nigeria.
Keywords
Cardiology Care, Delivered, Cancer Patients, Nigeria
To cite this article
Alikor Chizindu Akubudike, Weje Chituru Chioma, A Survey of the Cardiology Care Delivered to Cancer Patients in Nigeria, Cancer Research Journal. Vol. 8, No. 1, 2020, pp. 8-12. doi: 10.11648/j.crj.20200801.12
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Ferlay J, Steliarova-Foucher E, Lortet-TieulentJ, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-1403. Google Scholar, Crossref Pub Med.
[2]
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220–241. Google Scholar Crossref Pub Med.
[3]
Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments Nat Rev Cardiol 2015; 12: 620. Google Scholar Crossref Pub Med.
[4]
Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall M, Chow EJ, Sklar CA, Mulrooney DA, Mertens AC, Border W, Durand JB, Robison LL, Meacham LR. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013; 31: 3673–3680. Google Scholar Crossref Pub Med.
[5]
Subar M, Lin W, Chen W, Pittman DG. Lack of uniformity in cardiac assessment during trastuzumab therapy. Breast J 2011; 17: 383–90.
[6]
Civelli M, Cardinale D, Martinoni A, Lamantia G, Colombo N, Colombo Aet al. Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol 2006; 111: 120–6.
[7]
Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57: 2263–70.
[8]
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients trea.
[9]
Colombo A, Cardinale D. Using cardiac biomarkers and treating cardiotoxicity in cancer. Future Cardiol 2013; 9: 105–18.
[10]
Cardiology care delivered to cancer patients; a survey of the Council of Cardio-oncology and of the Council for cardiology practice of the European Society of Cardiology. 2019.
[11]
Zamorano JL, Lancelloti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan D, Lip GYH, Lyon AR; 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology; European Heart Journal, Volume 37, Issue 36, 21 September 2016, Pages 2768-2801, https://doi.org/10.1093/eurheartj/ehw211.
[12]
Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ, Asteggiano R. Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council. Eur Heart J. 2018 Aug 6. [Epub ahead of print].
[13]
European Partnership Action Against Cancer consensus group, Borras JM, Albreht T, Audisio R, Briers E, Casali P, Esperou H, Grube B, Hamoir M, Henning G, Kelly J, Knox S, Nabal M, Pierotti M, Lombardo C, van Harten W, Poston G, Prades J, Sant M, Travado L, Valentini V, van de Velde C, van den Bogaert S, van den Bulcke M, van Hoof E, van den Neucker I, Wilson R. Policy statement on multidisciplinary cancer care. Eur J Cancer. 2014; 50: 475-80.
[14]
Parent S, Pituskin E, Paterson DI. The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease. Can J Cardiol. 2016; 32: 847-51.
[15]
Nancarrow SA, Booth A, Ariss S, Smith T, Enderby P, Roots A. Ten principles of good interdisciplinary team work. Hum Resour Health. 2013; 11: 19.
[16]
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014; 15: 1063-93.
Browse journals by subject